|
See related Cervarix vaccine information |
|
|
|
Manufacturer |
GlaxoSmithKline |
|
Distributor |
Hong Kong: Zuellig |
|
Contents |
Human Papillomavirus vaccine types 16 & 18 (recombinant, AS04 adjuvanted) |
|
Indications |
Prevention of cervical cancer in females 10-45 yr, by protecting against incident & persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN), CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by human papillomavirus (HPV) types 16 & 18.
Click to view Cervarix detailed prescribing infomation |
|
Dosage |
Three 0.5-mL doses administered IM in the deltoid region at 0, 1, 6 mth schedule.
Click to view Cervarix detailed prescribing infomation |
|
Overdosage |
View Cervarix overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Cervarix detailed prescribing infomation |
|
Special Precautions |
Acute severe febrile illness (postpone vaccination). Anaphylactic event following administration. Thrombocytopenia or any coagulation disorder. Do not administer intravascularly or intradermally. Not for treatment of persistent infection or HPV-related lesions. Does not prevent progression of established HPV-related lesions present at the time of vaccination. Not a substitute for regular cytological screening or for precautions against exposure to HPV & STD. Pregnancy & lactation.
Click to view Cervarix detailed prescribing infomation |
|
Adverse Drug Reactions |
Inj site reaction (eg pain, redness, swelling), headache, myalgia, fatigue. GI symptoms, itching/pruritus, rash, urticaria, arthralgia, fever (≥38°C).
View ADR Monitoring Form |
|
Drug Interactions |
Immunosuppressants.
View more drug interactions with Cervarix |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Cervarix storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Cervarix description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Cervarix mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Cervarix vaccine (inj) |
|
Cervarix (pre-filled syringe) 0.5 mL x 1's |
 |
|
|
|
Manufacturer: |
GlaxoSmithKline |
|
Distributor: |
Hong Kong: Zuellig |
|
 |
|
|
|
